Myriad Genetics Inc. announced it will present new data in eight abstracts at the 2025 San Antonio Breast Cancer Symposium (SABCS). The presentations will include updates on the Precise® Molecular Residual Disease (MRD) Test and the MyRisk® Hereditary Cancer Test. The Precise MRD Test, currently available for research use only, utilizes whole genome sequencing to achieve high sensitivity and specificity in detecting circulating tumor DNA (ctDNA), particularly in low-tumor-shedding cancers such as breast cancer. The data covers studies on MRD detection and its correspondence with clinical outcomes, as well as insights into germline and somatic testing and polygenic risk assessment. Some results are scheduled to be presented at SABCS, including findings from the MONITOR-Breast and MONSTAR-SCREEN-3 projects.